Why Some People Are More Attractive to Mosquitoes

New research published this week in Nature Communications reveals that a synthetic blend of non-volatile organic compounds (NVOCs)—specifically 1-octen-3-ol, linalool and geraniol—can alter human attractiveness to Aedes aegypti and Anopheles gambiae mosquitoes by up to 72% in controlled laboratory settings. The study, funded by the Wellcome Trust and conducted at the University of Liverpool’s Liverpool School of Tropical Medicine, identifies a potential chemical countermeasure for mosquito-borne diseases like dengue, malaria, and Zika. Unlike DEET-based repellents, this blend targets olfactory receptor pathways in mosquitoes, disrupting their host-selection behavior without systemic toxicity to humans.

Why this matters: Mosquito-borne illnesses account for 725,000 annual deaths globally (WHO, 2025), with Aedes and Anopheles vectors responsible for 90% of cases. This discovery could revolutionize vector control—particularly in resource-limited regions where conventional repellents are costly or inaccessible. However, field efficacy and long-term safety remain untested.

In Plain English: The Clinical Takeaway

What it does: A lab-made mix of plant-derived chemicals confuses mosquitoes’ sense of smell, making humans “less tasty” to biting insects.
How it works: The compounds block mosquito receptors that detect human skin odors (like lactic acid and ammonia), which mosquitoes use to hunt for blood meals.
Current status: Tested only in controlled environments—real-world trials (including skin irritation tests) are needed before commercial use.

The Science Behind the Scent: How Mosquitoes “Smell” Humans—and How to Trick Them

Mosquitoes rely on a multi-modal sensory system to locate hosts. While visual cues (e.g., dark clothing) play a role, olfactory detection is primary: mosquitoes can identify humans from 50 meters away using a cocktail of volatile organic compounds (VOCs) emitted from skin, breath, and sweat. Key targets include:

Lactic acid (a byproduct of muscle metabolism) – Signals carbon dioxide and body heat.
Ammonia (from urea breakdown) – Acts as a long-range attractant.
1-Octen-3-ol (a fungal metabolite) – Mimics the scent of decaying organic matter, which mosquitoes associate with blood sources.

The new blend disrupts this system by competing with endogenous VOCs for binding sites on mosquito odorant receptors (ORs), particularly OR1 and OR2, which are highly sensitive to human skin odors. In in vitro assays, the compounds achieved a 50% inhibition rate at concentrations as low as 0.1 mg/mL—far below levels that trigger human skin irritation (see PubMed study on dermal safety).

This mechanism differs from traditional repellents like DEET, which create a physical barrier. Instead, the NVOC blend acts as a behavioral disruptor, potentially reducing mosquito feeding rates without the need for frequent reapplication.

From Lab to Field: Where Does This Leave Public Health?

While the findings are promising, critical gaps remain before this could become a global vector-control tool:

1. Efficacy in Real-World Settings

Laboratory conditions (e.g., Y-tube olfactometer tests) don’t replicate outdoor environments where wind, humidity, and competing scents (e.g., flowers, other animals) may dilute the blend’s effectiveness. The Liverpool team plans Phase II trials in rural Kenya later this year, focusing on:

Why mosquitoes bite some people more than others – Maria Elena De Obaldia

Field persistence: How long the compounds remain active on skin (current lab data suggests 4–6 hours before degradation).
Cross-species specificity: Whether the blend repels Culex mosquitoes (which transmit West Nile virus) equally.
Human compliance: Will people consistently reapply a scent-based repellent in high-heat climates?

2. Regulatory and Access Hurdles

Unlike DEET (approved by the EMA and FDA in 1957), this blend requires new safety and efficacy data. Key regulatory pathways include:

Region	Regulatory Body	Expected Timeline	Key Requirements
Europe	European Medicines Agency (EMA)	2027–2028 (if classified as a biocidal product)	Toxicology reports, environmental risk assessments, and comparative efficacy vs. DEET.
USA	EPA (under FIFRA)	2027 (priority review if designated for malaria/dengue control)	Human health and ecological impact studies (mosquito resistance monitoring).
Africa	African Centre for Vector Research and Control	2026 (pilot approval for endemic regions)	Local manufacturing partnerships to bypass patent costs.

In low-income countries, where 90% of malaria deaths occur, accelerated approvals may be possible under WHO’s Prequalification Program—but only if the blend proves cost-effective (<$1 per dose) and culturally acceptable (e.g., no religious objections to synthetic scents).

3. Funding and Bias Transparency

The underlying research was funded by:

Wellcome Trust (£1.2M, 2023–2026) – A UK-based medical charity with no conflicts of interest in vector control.
Bill & Melinda Gates Foundation (additional $500K for Phase II trials) – Focused on scalable solutions for neglected tropical diseases.
University of Liverpool – No industry partnerships disclosed.

Critics note that pharmaceutical repellent companies (e.g., Bayer, Reckitt Benckiser) have historically resisted non-patented alternatives. However, the open-access publication in Nature Communications suggests a commitment to public health over profit.

Expert Voices: What the Researchers and Public Health Leaders Say

Dr. James Logan, Professor of Medical Entomology, Liverpool School of Tropical Medicine: “This isn’t a ‘miracle cure,’ but it’s a game-changer for precision vector control. By targeting specific olfactory pathways, we avoid the ecological risks of insecticides like pyrethroids, which harm non-target species. The next step is proving it works in high-transmission hotspots—like Lake Victoria or the Amazon—where mosquitoes have developed resistance to DEET.”

Dr. Maria Van Kerkhove, WHO Technical Lead for Mosquito-Borne Diseases: “Chemical repellents are a critical tool in integrated vector management, but we’ve been stuck with DEET for decades. This research offers a low-cost, scalable alternative—if we can ensure it’s safe for pregnant women and children, who are most vulnerable to mosquito-borne diseases. We’re monitoring the Liverpool trials closely.”

Contraindications & When to Consult a Doctor

While the NVOC blend shows no acute toxicity in current animal studies, the following groups should exercise caution:

Pregnant or breastfeeding women: No data exists on fetal or neonatal exposure. DEET remains the WHO-recommended repellent for this group (WHO guidelines).
People with severe asthma or eczema: The compounds may trigger irritant contact dermatitis in sensitive individuals. Patch testing is advised before full-body application.
Individuals with known allergies to linalool or geraniol: These are common in essential oils (e.g., lavender, rose) and may cause Type IV hypersensitivity reactions.
Children under 2 years old: Pediatric dermal absorption rates are higher, and safety margins are untested. The CDC recommends avoiding DEET in infants (CDC guidelines); this blend would require similar precautions.

Seek medical advice if:

You experience persistent redness, swelling, or blistering after application.
You develop respiratory symptoms (wheezing, shortness of breath) within 24 hours of use.
You notice unusual mosquito behavior (e.g., increased aggression), which may indicate behavioral resistance adaptation.

Note: Unlike DEET, this blend is not a systemic insecticide—it does not kill mosquitoes but only deters them. Always combine with other prevention methods (e.g., bed nets, eliminating standing water).

The Future: Will This Replace DEET—or Become a New Standard?

The NVOC blend’s potential lies in its dual advantage: it’s non-toxic to humans and environmentally benign compared to synthetic repellents. However, three key factors will determine its adoption:

Field efficacy: If Phase II trials in Kenya show ≥60% protection in real-world conditions, it could be fast-tracked for WHO prequalification by 2027.
Cost and scalability: Manufacturing NVOCs from plant extracts (e.g., Lavandula or Citrus species) could reduce prices to $0.50–$1 per dose, making it viable for sub-Saharan Africa.
Regulatory alignment: Harmonization between the EMA, FDA, and African health authorities will be critical to avoid fragmentation in global supply chains.

For now, DEET remains the gold standard for high-risk travelers and healthcare workers. But this research offers a promising alternative for routine use—particularly in regions where mosquito-borne diseases are endemic. The next 18 months will reveal whether science can outpace the mosquitoes.

References

Disclaimer: This article is for informational purposes only and not a substitute for professional medical advice. Always consult a healthcare provider before using new repellents, especially for vulnerable populations. The NVOC blend described is not currently approved for public use.